Search
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Products: Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 7 ADETPemrametostat
go.drugbank.com/drugs/DB19170InvestigationalPemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)).
Synonyms: Protein arginine methyltransferase 5 inhibitor gsk3326595, 4-pyrimidinecarboxamide, 6-((1-acetyl-4-piperidinyl)amino)-n-((2s)-3-(3,4-dihydro-2(1h)-isoquinolinyl)-2-hydroxypropyl)-Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSynonyms: 19-nortestosterone decanoateEtoposide toniribate
go.drugbank.com/drugs/DB17255InvestigationalSynonyms: ((4rs)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl4-((5r,5ar,8ar,9s)-9-((4,6-o-((1r)-ethane-1,1-diyl)-.beta., Carbonic acid, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-((5r,5ar,8ar,9s)-9-((4,6-o-(1r)-ethylidene-.beta.Ritonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalRitonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].[L40094] … Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug
Mixtures: LOPIMUNE ® + RITONAVIR 10 MG - PELLETS EN CÁPSULAS ORALES, ALUVIA (100 MG/25 MG)Categories: Heterocyclic Compounds, 1-Ring, Experimental Unapproved Treatments for COVID-19Diphenhydramine
go.drugbank.com/drugs/DB01075ApprovedInvestigationalHowever, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. … As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Synonyms: N-(2-(diphenylmethoxy)ethyl)-N,N-dimethylamine, 2-(benzhydryloxy)-N,N-dimethylethylamineInternational brands: Dormarex 2Coagulation Factor IX Human
go.drugbank.com/drugs/DB13152ApprovedInvestigationalFactor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETCategories: coagulation factor IX, II, VII and X in combinationTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.
Categories: Experimental Unapproved Treatments for COVID-19, Cytochrome P-450 CYP3A InducersProducts: ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET, ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 4 ADETDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexSynonyms: 4-AP, 4-AminopyridineDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalFDA approved on October 14, 2011. … Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesSynonyms: 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 1,2-Dimethyl-3-hydroxypyrid-4-one